Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
Q1 2026 vs. Q4 2025
How the institutions holding Estrella Immunopharma, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 15 | 1 | 16 | +2 |
| Shares | 999.6K | 448.8K | 5.18M | +4.63M (+840.2%) |
| Value | $1.56M | $700.1K | $5.49M | +$4.63M (+539.1%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Estrella Immunopharma, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 4,099,000 | $4.34M | 0.14% |
| Vanguard Capital Management LLC | 382,469 | $405.4K | 0.00% |
| Wells Fargo & Company | 264,388 | $280.3K | 0.00% |
| Vanguard Fiduciary Trust Co | 64,921 | $68.8K | 0.00% |
| US Bancorp | 16,904 | $17.9K | 0.00% |
| Tower Research Capital LLC (TRC) | 4,859 | $5.15K | 0.00% |
| Toronto Dominion Bank | 1,089 | $1.15K | 0.00% |
| Wolverine Asset Management LLC | 468 | $496 | 0.00% |
Sold out (6)
Institutions that held Estrella Immunopharma, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Citadel Advisors LLC | 64,394 | $100.5K |
| Marshall Wace, LLP | 56,236 | $87.7K |
| XTX Topco Ltd | 49,472 | $77.2K |
| Quadrature Capital Ltd | 27,781 | $43.3K |
| Jane Street Group, LLC | 10,441 | $16.3K |
| Bank of America Corp | 10 | $16 |
Not filed for Q1 2026 yet (1)
Institutions that held Estrella Immunopharma, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 448,765 | $700.1K |